Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Rating of “Buy” by Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $43.17.

ORKA has been the topic of a number of research analyst reports. Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. TD Cowen began coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a “buy” rating on the stock. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, October 31st.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Great Point Partners LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $12,614,000. FMR LLC acquired a new position in Oruka Therapeutics during the third quarter worth $114,763,000. Finally, The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics during the third quarter valued at about $1,037,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $25.65 on Thursday. The business’s 50 day moving average price is $26.83. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88. The stock has a market cap of $31.04 million, a PE ratio of -4.26 and a beta of 0.87.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.